🚨 Perioperative anaphylaxis is rare but deadly. This review spotlights evolving triggers, atypical signs, epinephrine-first care and prevention planning. @ASALifeline#Anaphylaxis#Anesthesiology
🔗 https://t.co/gFF4i5NslR
🧬 A spinal mixed histiocytosis relapse after BRAF-mutated skull LCH responded to BRAF/MEK inhibition, highlighting the value of molecularly targeted therapy. @Histiocytosis#Histiocytosis#BRAF#TargetedTherapy
🔗 https://t.co/Gmt7w2Jbz7
👧 Updated Chinese guidelines for pediatric low-grade gliomas synthesize modern evidence and expert consensus for diagnosis, treatment and family-centered care. @NBTStweets#PediatricGlioma#NeuroOncology#Guidelines
🔗 https://t.co/oZlEADCjoP
🧮 Normalization can boost within-dataset ML on omics data yet worsen cross-dataset generalization; LASSO without normalization often traveled best. @ISCB#MachineLearning#Transcriptomics#CancerAI
🔗 https://t.co/cy0Rv5jGzo
🧬 BET/BRD4 inhibition remains promising in solid tumors, but toxicity, resistance and weak monotherapy responses push the field toward selective inhibitors and combos. @AACR#BETinhibitors#CancerTherapy#BRD4
🔗 https://t.co/dlgAlrCtiq
🧫 Micro- and nanoplastics may affect IBD through barrier injury, immune activation and microbiome shifts—standardized human studies are urgently needed. @CrohnsColitisFn#IBD#Microplastics#GutHealth
🔗 https://t.co/CK77sbgYJJ
😴 OSA may shape lung cancer risk via intermittent hypoxia, immune remodeling and pro-survival pathways; CPAP adherence could matter, but better studies are needed. @SleepResearchSoc
#SleepApnea#LungCancer#Hypoxia
🔗 https://t.co/CrlOLv1538
🧪 In NSCLC, PD-L1 testing depends on preanalytics. This study probes whether ischemia/fixation windows from control tissue translate to real tumor samples. @IASLC#LungCancer#PDL1#Pathology
🔗 https://t.co/SvMBnrFyyp
🧬 Cervical cancer prevention keeps evolving—from Pap to HPV testing, digital pathology and AI—yet implementation quality and access remain decisive. @SGO_org#CervicalCancer#CancerScreening#AI
🔗 https://t.co/WgDbMs17LG
🩸 AML immunotherapy works best in combinations: checkpoints, CAR-T, ADCs, bispecifics and vaccines paired with chemo may overcome single-agent limits. @ASH_hematology#AML#Immunotherapy#Hematology
🔗 https://t.co/ELIPAK2s4o
🌿 Forsythoside B shows promise in osteoarthritis models via Nrf2/HO-1 activation and NF-κB/MAPK dampening, but translational R&D questions remain. @OAC_Open#Osteoarthritis#Nrf2#NaturalProducts
🔗 https://t.co/IrUOK9hVfq